［1］SIEGEL RL,MILLER KD,WAGLE NS,et al.Cancer statistics,2023 ［J］.CA Cancer J Clin,2023,73(1):17-48.
［2］TORRES W,PEREZ JL,DIAZ MP,et al.The role of specialized pro-resolving lipid mediators in inflammation-induced carcinogenesis ［J］.Int J Mol Sci,2023,24(16):12623.
［3］PARADA-CRUZ B,AZTATZI-AGUILAR OG,RAMIREZ-MARTINEZ G,et al.Inflammation-and cancer-related microRNAs in rat renal cortex after subchronic exposure to fluoride ［J］.Chem Biol Interact,2023,379(3):110519.
［4］LOO SW,PUI TS.Cytokine and cancer biomarkers detection:the dawn of electrochemical paper-based biosensor ［J］.Sensors (Basel),2020,20(7):1854.
［5］ZHAO L,HU H,GUSTAFSSON JA,et al.Nuclear receptors in cancer inflammation and immunity ［J］.Trends Immunol,2020,41(2):172-185.
［6］PSILOPATIS I,VRETTOU K,NOUSIOPOULOU E,et al.The role of peroxisome proliferator-activated receptors in polycystic ovary syndrome ［J］.J Clin Med,2023,12(8):2912.
［7］WAGNER N,WAGNER KD.Peroxisome proliferator-activated receptors and the hallmarks of cancer ［J］.Cells,2022,11(15):2432.
［8］STRAUS DS,GLASS CK.Anti-inflammatory actions of PPAR ligands:new insights on cellular and molecular mechanisms ［J］.Trends Immunol,2007,28(12):551-558.
［9］DAYNES RA,JONES DC.Emerging roles of PPARs in inflammation and immunity ［J］.Nat Rev Immunol,2002,2(10):748-759.
［10］TONTONOZ P,SPIEGELMAN BM.Fat and beyond:the diverse biology of PPARgamma ［J］.Annu Rev Biochem,2008,77(12):289-312.
［11］MONSALVE FA,PYARASANI RD,DELGADO-LOPEZ F,et al.Peroxisome proliferator-activated receptor targets for the treatment of metabolic diseases ［J］.Mediators Inflamm,2013,2013:549627.
［12］MANTOVANI A,ALLAVENA P,SICA A,et al.Cancer-related inflammation ［J］.Nature,2008,454(7203):436-444.
［13］OHSHIMA H,TATEMICHI M,SAWA T.Chemical basis of inflammation-induced carcinogenesis ［J］.Arch Biochem Biophys,2003,417(1):3-11.
［14］LEUTI A,FAZIO D,FAVA M,et al.Bioactive lipids,inflammation and chronic diseases ［J］.Adv Drug Deliv Rev,2020,159(16):133-169.
［15］WANG JL,HUA SN,BAO HJ,et al.Pyroptosis and inflammasomes in cancer and inflammation ［J］.Med Comm (2020),2023,4(5):e374.
［16］CARIOU B,CHARBONNEL B,STAELS B.Thiazolidinediones and PPARgamma agonists:time for a reassessment ［J］.Trends Endocrinol Metab,2012,23(5):205-215.
［17］CHEN Y,JIMENEZ AR,MEDH JD.Identification and regulation of novel PPAR-gamma splice variants in human THP-1 macrophages ［J］.Biochim Biophys Acta,2006,1759(1-2):32-43.
［18］LI D,HE L,YUAN C,et al.Peroxisome proliferator-activated receptor gamma agonist pioglitazone alleviates hemorrhage-induced thalamic pain and neuroinflammation ［J］.Int Immunopharmacol,2023,124(Pt B):110991.
［19］FAJAS L,AUBOEUF D,RASPE E,et al.The organization,promoter analysis,and expression of the human PPARgamma gene ［J］.J Biol Chem,1997,272(30):18779-18789.
［20］FEIGE JN,GELMAN L,MICHALIK L,et al.From molecular action to physiological outputs:peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions ［J］.Prog Lipid Res,2006,45(2):120-159.
［21］LEMBERGER T,DESVERGNE B,WAHLI W.Peroxisome proliferator-activated receptors:a nuclear receptor signaling pathway in lipid physiology ［J］.Annu Rev Cell Dev Biol,1996,12(4):335-363.
［22］CAPITAO AMF,LOPES-MARQUES M,PASCOA I,et al.An ancestral nuclear receptor couple,PPAR-RXR,is exploited by organotins ［J］.Sci Total Environ,2021,797(16):149044.
［23］VARGA T,CZIMMERER Z,NAGY L.PPARs are a unique set of fatty acid regulated transcription factors controlling both lipid metabolism and inflammation ［J］.Biochim Biophys Acta,2011,1812(8):1007-1022.
［24］CANTINI G,LOMBARDI A,BORGOGNI E,et al.Peroxisome-proliferator-activated receptor gamma (PPARgamma) is required for modulating endothelial inflammatory response through a nongenomic mechanism ［J］.Eur J Cell Biol,2010,89(9):645-653.
［25］CHAKRABORTY C,SHARMA AR,SHARMA G,et al.The interplay among miRNAs,major cytokines,and cancer-related inflammation ［J］.Mol Ther Nucleic Acids,2020,20(2):606-620.
［26］ADACHI M,KUROTANI R,MORIMURA K,et al.Peroxisome proliferator activated receptor gamma in colonic epithelial cells protects against experimental inflammatory bowel disease ［J］.Gut,2006,55(8):1104-1113.
［27］SU CG,WEN X,BAILEY ST,et al.A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response ［J］.J Clin Invest,1999,104(4):383-389.
［28］TERESI RE,WAITE KA.PPARgamma,PTEN,and the fight against cancer ［J］.PPAR Res,2008,2008(23):932632.
［29］PATEL L,PASS I,COXON P,et al.Tumor suppressor and anti-inflammatory actions of PPARgamma agonists are mediated via upregulation of PTEN ［J］.Curr Biol,2001,11(10):764-768.
［30］CHEN F,WANG M,O'CONNOR JP,et al.Phosphorylation of PPARgamma via active ERK1/2 leads to its physical association with p65 and inhibition of NF-kappabeta ［J］.J Cell Biochem,2003,90(4):732-744.
［31］WANG LH,YANG XY,ZHANG X,et al.Transcriptional inactivation of STAT3 by PPARgamma suppresses IL-6-responsive multiple myeloma cells ［J］.Immunity,2004,20(2):205-218.
［32］PASCUAL G,FONG AL,OGAWA S,et al.A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma ［J］.Nature,2005,437(7059):759-763.
［33］HOU Y,MOREAU F,CHADEE K.PPARgamma is an E3 ligase that induces the degradation of NFkappaB/p65 ［J］.Nat Commun,2012,3(2):1300.
［34］LEE EJ,KIM SJ,HAHN YI,et al.15-Keto prostaglandin E(2) suppresses STAT3 signaling and inhibits breast cancer cell growth and progression ［J］.Redox Biol,2019,23(14):101175.
［35］LU D,HAN C,WU T.15-PGDH inhibits hepatocellular carcinoma growth through 15-keto-PGE2/PPARgamma-mediated activation of p21WAF1/Cip1 ［J］.Oncogene,2014,33(9):1101-1112.
［36］RATAJCZAK MZ,ZUBA-SURMA E,KUCIA M,et al.The pleiotropic effects of the SDF-1-CXCR4 axis in organogenesis,regeneration and tumorigenesis ［J］.Leukemia,2006,20(11):1915-1924.
［37］SHI Y,RIESE DJ,SHEN J.The role of the CXCL12/CXCR4/CXCR7 chemokine axis in cancer ［J］.Front Pharmacol,2020,11(4):574667.
［38］ROVITO D,GIONFRIDDO G,BARONE I,et al.Ligand-activated PPARgamma downregulates CXCR4 gene expression through a novel identified PPAR response element and inhibits breast cancer progression ［J］.Oncotarget,2016,7(40):65109-65124.
［39］ZHANG J,ZHANG Y,XIAO F,et al.The peroxisome proliferator-activated receptor gamma agonist pioglitazone prevents NF-kappaB activation in cisplatin nephrotoxicity through the reduction of p65 acetylation via the AMPK-SIRT1/p300 pathway ［J］.Biochem Pharmacol,2016,101(11):100-111.
［40］GUTTING T,WEBER CA,WEIDNER P,et al.PPARgamma-activation increases intestinal M1 macrophages and mitigates formation of serrated adenomas in mutant KRAS mice ［J］.Oncoimmunology,2018,7(5):e1423168.
［41］BELVISI MG,MITCHELL JA.Targeting PPAR receptors in the airway for the treatment of inflammatory lung disease ［J］.Br J Pharmacol,2009,158(4):994-1003.
［42］MITCHELL JA,WARNER TD.Cyclo-oxygenase-2:pharmacology,physiology,biochemistry and relevance to NSAID therapy ［J］.Br J Pharmacol,1999,128(6):1121-1132.
［43］VANE JR.Introduction:mechanism of action of NSAIDs ［J］.Br J Rheumatol,1996,35 Suppl 1:1-3.
［44］ULRICH CM,BIGLER J,POTTER JD.Non-steroidal anti-inflammatory drugs for cancer prevention:promise,perils and pharmacogenetics ［J］.Nat Rev Cancer,2006,6(2):130-140.
［45］HIGUCHI T,TAKEUCHI A,MUNESUE S,et al.A nonsteroidal anti-inflammatory drug,zaltoprofen,inhibits the growth of extraskeletal chondrosarcoma cells by inducing PPARgamma,p21,p27,and p53 ［J］.Cell Cycle,2023,22(8):939-950.
［46］BADAWI AF,BADR MZ.Chemoprevention of breast cancer by targeting cyclooxygenase-2 and peroxisome proliferator-activated receptor-gamma (Review) ［J］.Int J Oncol,2002,20(6):1109-1122.
［47］EIBL G,TAKATA Y,BOROS LG,et al.Growth stimulation of COX-2-negative pancreatic cancer by a selective COX-2 inhibitor ［J］.Cancer Res,2005,65(3):982-990.
［48］HIGUCHI T,TAKEUCHI A,MUNESUE S,et al.Anti-tumor effects of a nonsteroidal anti-inflammatory drug zaltoprofen on chondrosarcoma via activating peroxisome proliferator-activated receptor gamma and suppressing matrix metalloproteinase-2 expression ［J］.Cancer Med,2018,7(5):1944-1954.
［49］DU H,CHEN X,ZHANG J,et al.Inhibition of COX-2 expression by endocannabinoid 2-arachidonoylglycerol is mediated via PPAR-gamma ［J］.Br J Pharmacol,2011,163(7):1533-1549.
［50］PASDARAN A,HASSANI B,TAVAKOLI A,et al.A review of the potential benefits of herbal medicines,small molecules of natural sources,and supplements for health promotion in lupus conditions ［J］.Life (Basel),2023,13(7):1589.
［51］SIDDIQUI AM,CUI X,WU R,et al.The anti-inflammatory effect of curcumin in an experimental model of sepsis is mediated by up-regulation of peroxisome proliferator-activated receptor-gamma ［J］.Crit Care Med,2006,34(7):1874-1882.
［52］FENG X,WENG D,ZHOU F,et al.Activation of PPARgamma by a natural flavonoid modulator,apigenin ameliorates obesity-related inflammation via regulation of macrophage polarization ［J］.EBioMedicine,2016,9(9):61-76.
［53］ONG SKL,SHANMUGAM MK,FAN L,et al.Focus on formononetin:anticancer potential and molecular targets ［J］.Cancers (Basel),2019,11(5):1589.
［54］MA Z,JI W,FU Q,et al.Formononetin inhibited the inflammation of LPS-induced acute lung injury in mice associated with induction of PPAR gamma expression ［J］.Inflammation,2013,36(6):1560-1566.
［55］CHOI CI.Astaxanthin as a peroxisome proliferator-activated receptor (PPAR) modulator:its therapeutic implications ［J］.Mar Drugs,2019,17(4):242.
［56］INOUE M,TANABE H,MATSUMOTO A,et al.Astaxanthin functions differently as a selective peroxisome proliferator-activated receptor gamma modulator in adipocytes and macrophages ［J］.Biochem Pharmacol,2012,84(5):692-700.
［57］LIU S,SU M,SONG SJ,et al.An anti-inflammatory PPAR-gamma agonist from the Jellyfish-Derived fungus penicillium chrysogenum J08NF-4 ［J］.J Nat Prod,2018,81(2):356-363.
［58］LONKAR P,DEDON PC.Reactive species and DNA damage in chronic inflammation:reconciling chemical mechanisms and biological fates ［J］.Int J Cancer,2011,128(9):1999-2009.
［59］SCHETTER AJ,HEEGAARD NH,HARRIS CC.Inflammation and cancer:interweaving microRNA,free radical,cytokine and p53 pathways ［J］.Carcinogenesis,2010,31(1):37-49.
［60］GRIVENNIKOV SI,GRETEN FR,KARIN M.Immunity,inflammation,and cancer ［J］.Cell,2010,140(6):883-899.
［61］FARAZI TA,SPITZER JI,MOROZOV P,et al.miRNAs in human cancer ［J］.J Pathol,2011,223(2):102-115.
［62］HEATH VL,BICKNELL R.Anticancer strategies involving the vasculature ［J］.Nat Rev Clin Oncol,2009,6(7):395-404.
［63］RINI BI.Metastatic renal cell carcinoma:many treatment options,one patient ［J］.J Clin Oncol,2009,27(19):3225-3234.
［64］IVY SP,WICK JY,KAUFMAN BM.An overview of small-molecule inhibitors of VEGFR signaling ［J］.Nat Rev Clin Oncol,2009,6(10):569-579.
［65］MENA AC,PULIDO EG,GUILLEN-PONCE C.Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor:sunitinib ［J］.Anticancer Drugs,2010,21 Suppl 1:S3-S11.
［66］ALLEN M,LOUISE JONES J.Jekyll and Hyde:the role of the microenvironment on the progression of cancer ［J］.J Pathol,2011,223(2):162-176.
［67］FINGER EC,GIACCIA AJ.Hypoxia,inflammation,and the tumor microenvironment in metastatic disease ［J］.Cancer Metastasis Rev,2010,29(2):285-293.
［68］BISWAS SK,MANTOVANI A.Macrophage plasticity and interaction with lymphocyte subsets:cancer as a paradigm ［J］.Nat Immunol,2010,11(10):889-896.
［69］LAZENNEC G,RICHMOND A.Chemokines and chemokine receptors:new insights into cancer-related inflammation ［J］.Trends Mol Med,2010,16(3):133-144.
［70］GRZESIAK JJ,TRAN CAO HS,BURTON DW,et al.Knockdown of the beta(1) integrin subunit reduces primary tumor growth and inhibits pancreatic cancer metastasis ［J］.Int J Cancer,2011,129(12):2905-2915.
［71］KUSUMA N,DENOYER D,EBLE JA,et al.Integrin-dependent response to laminin-511 regulates breast tumor cell invasion and metastasis ［J］.Int J Cancer,2012,130(3):555-566.